448 patents currently held
86 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
40
Ending by 2030
Dec 2026
Next term end
232
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2037 · Medium confidence
Also notable
Ends Dec 2026 · High confidence
Also notable
Ends Aug 2034 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends Aug 2032 · Low confidence
Also notable
Ends Jun 2033 · High confidence
Also notable
Ends May 2039 · High confidence
Also notable
Ends May 2031 · High confidence
Heterocyclic Compounds as Immunomodulators
US 11,608,337
Cited by 43 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2037.
Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors
US 9,974,790
Cited by 74 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2026. A terminal disclaimer caps this term to an earlier patent's.
Bipyrazole Derivatives as Jak Inhibitors
US 9,382,231
The most cited patent in this portfolio, cited by 176 later US patents, top 5% of utility patents granted in 2016 in our data. Protection runs to 2034.
Sustained-Release Dosage Forms of Ruxolitinib
US 11,337,927
Cited by 22 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Heterocyclylamines as PI3K Inhibitors
US 9,730,939
Cited by 68 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Substituted Tricyclic Compounds as FGFR Inhibitors
US 11,840,534
Cited by 20 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Heterocyclic Compounds as Immunomodulators
US 11,414,433
Cited by 50 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Topical Formulation for a Jak Inhibitor
US 11,219,624
Cited by 12 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Dec 2027 · High confidence
The most cited patent in this portfolio, cited by 437 later US patents, top 1% of utility patents granted in 2009 in our data. Protection runs to 2027.
Also notable
Ends May 2034 · High confidence
Cited by 103 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
Also notable
Ends Aug 2030 · High confidence
Cited by 205 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 28 to 30, 2026 · next Nov 28
- 7 fees due Dec 4 to 27, 2026 · next Dec 4
- 5 fees due Jan 2 to 30, 2027 · next Jan 2
- 9 fees due Feb 1 to 28, 2027 · next Feb 1
- 5 fees due Mar 12 to 26, 2027 · next Mar 12
- 14 fees due Apr 1 to 24, 2027 · next Apr 1
- 8 fees due May 5 to 21, 2027 · next May 5
- 13 fees due Jun 1 to 30, 2027 · next Jun 1
- 8 fees due Jul 9 to 30, 2027 · next Jul 9
- 10 fees due Aug 6 to 27, 2027 · next Aug 6
- 12 fees due Sep 5 to 26, 2027 · next Sep 5
- 14 fees due Oct 7 to 28, 2027 · next Oct 7
- 6 fees due Nov 5 to 19, 2027 · next Nov 5
Recent changes
- Oct 29Assignment recorded on 1 record: Sokolsky, Alexander and 5 others to Incyte Corporation Recorded Oct 29, 2026, executed Aug 17, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76563, frame 925.
- 3 of the patents on this record were granted since Aug 23, 2026
- 6 terms have ended since Aug 23, 2026
- Oct 30 US 10,112,950 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LSD1 INHIBITORS · lapsed on the fee record
- Sep 23 US 8,841,318 Substituted Heterocycles as Janus Kinase Inhibitors · lapsed on the fee record
- Sep 16 US 8,835,423 Azepine Inhibitors of Janus Kinases · lapsed on the fee record
- Sep 4 US 10,065,963 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS · lapsed on the fee record
- Sep 2 US 8,822,511 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase · lapsed on the fee record
- Aug 30 US 11,427,597 Heteroaryl Amide Compounds as Sting Activators · lapsed on the fee record
What they patent
The largest of its 232 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,662,335 | Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,814,722 | Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,974,790 | Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 10,398,699 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS In force · High confidence | In force | High confidence | |
| US 10,639,310 | Heteroaryl Substituted Pyrrolo[2,3-b]pyridines and Pyrrolo[2,3-b]pyrimidines as Janus Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 11,331,320 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS In force · High confidence | In force | High confidence | |
| US 11,744,832 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS In force · High confidence | In force | High confidence | |
| US 7,910,108 | Sheddase Inhibitors Combined with CD30-Binding Immunotherapeutics for the Treatment of CD30 Positive Diseases In force · High confidence | In force | High confidence | |
| US 7,511,050 | Purinone Derivatives as HM74A Agonists In force · High confidence | In force | High confidence | |
| US 7,902,205 | Purinone Derivatives as HM74A Agonists In force · High confidence | In force | High confidence |
Also on record, not counted in the 448: 86 patents in force now held by others · 120 patents ended · 191 applications pending · 438 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.